Skip to main content
ZVRAZevra Therapeutics, Inc.Buy Wait7.5·$8.76
Buy WaitHigh Confidence
Investment thesis

Zevra Therapeutics combines a deep-value margin of safety and elite quality metrics with a consistent earnings-beat streak, though bearish insider selling and elevated short interest temper the setup.

Thesis pillars

  • Deep Value Margin Of Safety—
  • Elite Quality Compounder Metrics→Stable
  • Earnings Beat Streak Momentum→Stable
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Mar 9, 2026· older than 90 days

Full reasoning →

Open full analysis

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis

Temporary headwind edge

Buy WaitValueGrowthQualityHigh Confidence

Healthcare · Biotechnology

Wait for pullback to $8.27. Weak momentum — blocks BUY_NOW at $8.76. Engine's entry $8.27 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: MIPLYFFA (82.0%); Negative momentum.

Zevra Therapeutics is a commercial-stage rare disease company whose lead product, MIPLYFFA (arimoclomol), was FDA-approved in September 2024 for Niemann-Pick disease type C and generated approximately 82% of the company's 2025 revenue. Zevra also markets OLPRUVA for urea cycle... Read more

$8.76+128.4% A.UpsideScore 7.5/10#1 of 240 Biotechnology
QualityF-score8 / 9FCF yield9.83%
Entry $8.27(Default 5pct Sticky)Stop $7.69Target $20.01(analyst − 13%)A.R:R 8.6:1
Analyst consensus$23.00+162.6%8 analysts with price targets
$20.01our TP
$8.76price
$23.00mean
$35

Wait for pullback to $8.27. Weak momentum — blocks BUY_NOW at $8.76. Engine's entry $8.27 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: MIPLYFFA (82.0%); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Value play: 71% MoS with quality 8.7. | CRISIS regime: wait for market stabilization. Score 7.5/10, high confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 106d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.

10-K grounded · weekly refresh

About Zevra Therapeutics, Inc.

About Zevra Therapeutics, Inc.

Zevra Therapeutics derived approximately 82% of its 2025 revenue from MIPLYFFA (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C, which reached the U.S. market in November 2024 following a September 2024 FDA approval and had 161 patient enrollments as of December 31, 2025. The company also markets OLPRUVA for urea cycle disorders, though 2025 OLPRUVA revenue was just $0.8 million, and separately earns royalties on AZSTARYS, an ADHD treatment marketed by partner Commave through its affiliate Corium.

Zevra generates revenue primarily from U.S. commercial sales of MIPLYFFA, dispensed through a specialty pharmacy that manages benefits investigations for patients, supplemented by a Global Expanded Access Program that supplies arimoclomol in France, Germany, and other EU markets ahead of a Marketing Authorisation Application now under EMA review. AZSTARYS, an earlier product developed using Zevra's proprietary Ligand Activated Technology platform, is licensed to Commave, whose affiliate Corium handles U.S. commercialization; Zevra collects tiered royalties on net sales plus milestone payments that could reach $590.0 million in the aggregate under the amended license terms, and it received a $148.3 million cash infusion in April 2025 from selling a rare pediatric disease priority review voucher tied to MIPLYFFA's approval. Beyond its commercial products, Zevra is running a Phase 3 trial (DiSCOVER) of celiprolol for Vascular Ehlers-Danlos syndrome, with 52 of a planned 150 patients enrolled as of December 31, 2025, and holds two additional Phase 3-ready candidates built on its serdexmethylphenidate prodrug for idiopathic hypersomnia and narcolepsy.

Show full overview

Zevra's own risk factors go beyond simply naming MIPLYFFA as the revenue leader: they state the company is highly dependent on this one product for substantially all of its revenue, and that because NPC's patient population is so small, even modest shifts in prescribing patterns, patient identification rates, or reimbursement decisions could have a disproportionate effect on results. That concentration is compounded by Zevra's decision to scale back sales and marketing for OLPRUVA while it evaluates strategic alternatives, meaning the company's near-term revenue diversification away from MIPLYFFA is moving in reverse rather than forward even as celiprolol and the KP1077 franchise remain years from potential approval.

See also: Healthcare · Biotechnology

From Zevra Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 17, 2026

Recent Developments — Zevra Therapeutics, Inc.

Latest item Nov 17, 2026 · Generated 2026-11-22T11:27:14Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Mon, Mar 8, 2027106d to earnings· next earnings call

Thesis

Rewards
V7 crisis quality shield: -0.3 vs -1.5 (Q=8.7)
Sector modifier (Healthcare): +0.8
Strong earnings beat streak (4/4)
Risks
Concentration risk — Product: MIPLYFFA (82.0%)
Negative momentum

Key Metrics

P/E (TTM)7.2
P/E (Fwd)9.8
Mkt Cap$521M
EV/EBITDA6.8
Profit Mgn52.8%
ROE41.9%
Rev Growth44.9%
Beta0.99
DividendNone
Analysts with ratings15

Quality Signals

Piotroski F8/9MoatWideCompounder✓

Options Flow

P/C1.02bearish
IV99%elevated

Concentration Risks(10-K Item 1A)

  • HIGHProductMIPLYFFA82%
    10-K Item 1A: 'For the year ended December 31, 2025 we derived approximately 82% of our revenues from commercial sales of MIPLYFFA'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker·3 ceiling hits

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
2.2
Volume
3.3
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.1%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 2.2<4.5A.R:R 8.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 106d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
41 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $8.70Resistance $12.20

Price Targets

$8
$8
$20
A.Upside+128.4%
A.R:R8.6:1

Position Sizing

ConvictionHigh conviction
Suggested %0.6%
Max %1.2%
RegimeCrisis

Risk Alerts

! CRISIS regime: all BUY_NOW downgraded to BUY_WAIT
! momentum at 2.2 (below the engine's 4.5 threshold)

Earnings

B
B
B
B
4/4 beats
Next Earnings2027-03-08 (106d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ZVRA stock a buy right now?

Wait for pullback to $8.27. Weak momentum — blocks BUY_NOW at $8.76. Engine's entry $8.27 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: MIPLYFFA (82.0%); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Value play: 71% MoS with quality 8.7. | CRISIS regime: wait for market stabilization. Target $20.01 (+128.4%), stop $7.69 (−13.9%), A.R:R 8.6:1. Score 7.5/10, high confidence.

What is the ZVRA stock price target?

Take-profit target: $20.01 (+128.4% upside). Target $20.01 (+128.4%), stop $7.69 (−13.9%), A.R:R 8.6:1. Stop-loss: $7.69.

What are the risks of investing in ZVRA?

Concentration risk — Product: MIPLYFFA (82.0%); Negative momentum.

Is ZVRA overvalued or undervalued?

Zevra Therapeutics, Inc. trades at a P/E of 7.2 (forward 9.8). TrendMatrix value score: 8.9/10. Verdict: Buy (Wait for Entry).

What do analysts say about ZVRA?

15 analysts rate ZVRA, with a consensus score of 4.3/5. 8 analysts publish price targets averaging $23.

What does Zevra Therapeutics, Inc. do?Zevra Therapeutics is a commercial-stage rare disease company whose lead product, MIPLYFFA (arimoclomol), was...

Zevra Therapeutics is a commercial-stage rare disease company whose lead product, MIPLYFFA (arimoclomol), was FDA-approved in September 2024 for Niemann-Pick disease type C and generated approximately 82% of the company's 2025 revenue. Zevra also markets OLPRUVA for urea cycle disorders, though it is scaling back sales and marketing for that product, earns royalties on the partnered ADHD drug AZSTARYS, and is running a Phase 3 trial of celiprolol for Vascular Ehlers-Danlos syndrome.

Related stocks: PHAT (Phathom Pharmaceuticals, Inc.) · ADRX (ADARx Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I) · MGTX (MeiraGTx Holdings plc) · URGN (UroGen Pharma Ltd.)
Home › Stocks › ZVRA

Latest news

Latest News

The AI Journal116d agoLegal
Moomoo25d ago
The Manila Times123d agoEarnings
Quiver Quantitative123d agoEarnings
MarketBeat95d agoAnalyst
Investing.com India39d ago
Investing.com Canada39d ago
MarketBeat102d ago
MarketBeat102d ago
Investing.com UK102d ago
GuruFocus11d ago
Investing.com India74d ago
Investing.com India137d ago
Investing.com Nigeria5d agoAnalyst
TipRanks7d agoEarnings
Asianet Newsable9d agoFda Decision